JP2024522116A5 - - Google Patents

Info

Publication number
JP2024522116A5
JP2024522116A5 JP2023573353A JP2023573353A JP2024522116A5 JP 2024522116 A5 JP2024522116 A5 JP 2024522116A5 JP 2023573353 A JP2023573353 A JP 2023573353A JP 2023573353 A JP2023573353 A JP 2023573353A JP 2024522116 A5 JP2024522116 A5 JP 2024522116A5
Authority
JP
Japan
Prior art keywords
cancer cells
antibody construct
antibody
muc1
construct according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023573353A
Other languages
English (en)
Japanese (ja)
Other versions
JP7874113B2 (ja
JP2024522116A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/031431 external-priority patent/WO2022251695A2/en
Publication of JP2024522116A publication Critical patent/JP2024522116A/ja
Publication of JP2024522116A5 publication Critical patent/JP2024522116A5/ja
Application granted granted Critical
Publication of JP7874113B2 publication Critical patent/JP7874113B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023573353A 2021-05-28 2022-05-27 Muc1-c/細胞外ドメイン(muc1-c/ecd)に対する多重特異性抗体構築物 Active JP7874113B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163194597P 2021-05-28 2021-05-28
US63/194,597 2021-05-28
PCT/US2022/031431 WO2022251695A2 (en) 2021-05-28 2022-05-27 Multi-specific antibody constructs against the muc1-c/extracellular domain ( muc1-c/ecd)

Publications (3)

Publication Number Publication Date
JP2024522116A JP2024522116A (ja) 2024-06-11
JP2024522116A5 true JP2024522116A5 (cg-RX-API-DMAC7.html) 2025-05-02
JP7874113B2 JP7874113B2 (ja) 2026-06-15

Family

ID=84230363

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023573353A Active JP7874113B2 (ja) 2021-05-28 2022-05-27 Muc1-c/細胞外ドメイン(muc1-c/ecd)に対する多重特異性抗体構築物

Country Status (11)

Country Link
US (1) US20240262930A1 (cg-RX-API-DMAC7.html)
EP (1) EP4346890A4 (cg-RX-API-DMAC7.html)
JP (1) JP7874113B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240021828A (cg-RX-API-DMAC7.html)
CN (1) CN117769432A (cg-RX-API-DMAC7.html)
AU (1) AU2022283436A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024724A2 (cg-RX-API-DMAC7.html)
CA (1) CA3220049A1 (cg-RX-API-DMAC7.html)
IL (1) IL308881A (cg-RX-API-DMAC7.html)
MX (1) MX2023014109A (cg-RX-API-DMAC7.html)
WO (1) WO2022251695A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4644413A1 (en) * 2024-05-03 2025-11-05 Genmab B.V. Binding agents having altered fc-mediated effector functions
WO2026024841A1 (en) * 2024-07-24 2026-01-29 Astellas Us Llc Bispecific antibodies that bind cd3 and muc1 and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
JP5425180B2 (ja) * 2008-03-27 2014-02-26 ザイモジェネティクス, インコーポレイテッド PDGFRβおよびVEGF−Aを阻害するための組成物および方法
MX2011013722A (es) * 2009-06-18 2012-05-08 Wyeth Llc Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños.
CA2803391C (en) * 2010-06-22 2021-11-09 Neogenix Oncology, Inc. Npc1 antibodies that bind a muc5ac epitope
US20150038682A1 (en) * 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
CN106132992B (zh) * 2014-01-29 2020-08-07 达娜-法勃肿瘤研究所公司 针对muc1-c/胞外结构域(muc1-c/ecd)的抗体
US10617773B2 (en) * 2016-08-05 2020-04-14 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
EP3601357A1 (en) * 2017-03-29 2020-02-05 Glycotope GmbH Multispecific antibody constructs binding to muc1 and cd3
US11725060B2 (en) * 2017-07-20 2023-08-15 Aptevo Reserch and Development LLC Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods
AU2018366199A1 (en) * 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
EP3773621A4 (en) * 2018-03-27 2022-03-23 Systimmune, Inc. GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE
WO2019222428A1 (en) * 2018-05-16 2019-11-21 Arbele Limited Composition of bispecific antibodies and method of use thereof
EP3850010A1 (en) * 2018-09-11 2021-07-21 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Improved anti-flt3 antigen binding proteins

Similar Documents

Publication Publication Date Title
JP2022515318A5 (cg-RX-API-DMAC7.html)
EP3237006B1 (en) Bispecific tetravalent antibodies and methods of making and using thereof
Todorovska et al. Design and application of diabodies, triabodies and tetrabodies for cancer targeting
JP2021098733A5 (cg-RX-API-DMAC7.html)
JP2020533311A5 (ja) NKG2D、CD16およびNectin4に結合するタンパク質
JP2022513053A (ja) B7-H3のIgVドメインに対するモノクローナル抗体及びその使用
JP2020510653A5 (ja) Ceaを標的にする多重特異性結合タンパク質
JP2021511811A5 (cg-RX-API-DMAC7.html)
JP2020522474A5 (cg-RX-API-DMAC7.html)
JP2017503480A5 (cg-RX-API-DMAC7.html)
JP2023539501A5 (cg-RX-API-DMAC7.html)
RU2016125551A (ru) Биспецифические антигенсвязывающие конструкции против her2
JP2010535713A5 (cg-RX-API-DMAC7.html)
JP2023516004A5 (cg-RX-API-DMAC7.html)
JP2023534959A5 (cg-RX-API-DMAC7.html)
JP2022517920A5 (cg-RX-API-DMAC7.html)
CN103025760A (zh) 人源化egfr抗体
EP2850106A2 (en) Bispecific scfv immunofusion (bif)
JP2025038088A5 (cg-RX-API-DMAC7.html)
JP2022519120A5 (cg-RX-API-DMAC7.html)
CN111655733A (zh) 共价多特异性抗体
JP2024508808A5 (cg-RX-API-DMAC7.html)
JP2024542192A5 (cg-RX-API-DMAC7.html)
JP2025507817A5 (cg-RX-API-DMAC7.html)
JP2019505545A5 (cg-RX-API-DMAC7.html)